Inmode Earnings Call: Growth Intact, Margins Under Strain

Inmode ((INMD)) has held its Q1 earnings call. Read on for the main highlights of the call.

Inmode’s latest earnings call painted a cautiously constructive picture, with modest revenue growth and clear strategic progress offset by visible pressure on margins and earnings. Management highlighted a solid cash position, product pipeline advances and early signs of U.S. stabilization, but also acknowledged that higher costs, weaker profitability and macro headwinds are weighing on near‑term performance.

Revenue Growth

Inmode reported Q1 2026 revenue of $82.0 million, a 5% increase from $77.9 million a year earlier, with the improvement driven primarily by better U.S. performance. Management framed this as early evidence that recent commercial changes are gaining traction, though the growth rate remains relatively modest against a challenging backdrop for elective aesthetic procedures.

Solid International Mix and Growth

International revenue reached $38.7 million, accounting for 48% of total sales and growing about 2.65% year over year, underscoring the company’s geographic diversification. Inmode now operates in more than 100 countries, and Europe was cited as a particular bright spot, helping to soften the impact of softer conditions in other regions.

Strong Balance Sheet and Cash Generation

The company ended the quarter with $537.2 million in cash, cash equivalents, marketable securities and deposits, giving it substantial financial flexibility. Inmode also generated $15.4 million in cash from operating activities in Q1, demonstrating that the business continues to convert earnings into cash even as margins come under pressure.

Product Momentum — Laser Platforms

Newer laser platforms, including Pico and CO2 systems, made meaningful contributions to first‑quarter revenue and broadened the firm’s range of aesthetic procedures. Management is also developing an Erbium laser and is targeting regulatory clearance by year‑end, which would further expand the portfolio and potentially deepen customer adoption.

Sales Reorganization and Early Stabilization

In North America, Inmode has shifted to a unified commercial model under leadership installed late in 2025 and separated the Envision ophthalmology and optometry sales force into an independent 30‑rep team. Executives pointed to early stabilization, particularly in the U.S., with March described as a notably strong month, suggesting the restructuring is beginning to show benefits.

Capital Return and Strategic Optionality

The company has been active in returning capital to shareholders, repurchasing $127.4 million of stock in 2025 and an additional $52.7 million so far in 2026, totaling about 3.86 million shares year to date. Management emphasized that all capital allocation options remain open, including continued buybacks, potential acquisitions and future dividends, supported by the sizable cash balance.

Gross Margin Compression

Profitability at the gross level deteriorated, with GAAP gross margin dropping to 75% from 78% in Q1 2025 and non‑GAAP gross margin sliding to 75% from 79%. Leadership cautioned that newer laser platforms, while important for growth, are likely to exert further pressure on gross margins as the mix shifts and the company invests to build scale.

Rising Operating Expenses

GAAP operating expenses climbed 13.7% year over year to $51.5 million, reflecting heavier spending to support growth and restructuring. Sales and marketing costs rose to $42.9 million from $39.7 million, driven by the North American sales overhaul, international subsidiary build‑outs and higher commission expenses tied to commercial activity.

Operating Margin and Profitability Declines

Higher costs and lower gross margins fed through to weaker profitability, with GAAP operating margin at 12% in Q1 and non‑GAAP operating margin falling to 17% from 23% a year earlier. The six‑point drop underscores the near‑term trade‑off between investing in sales infrastructure and innovation versus maintaining historical margin levels.

Earnings Per Share Under Pressure

Earnings per share declined meaningfully, with GAAP diluted EPS down to $0.18 from $0.26 in Q1 2025, a drop of roughly 30.8%. On a non‑GAAP basis, diluted EPS fell to $0.25 from $0.31, or about 19.4%, highlighting that even after adjusting for certain items, profitability remains under strain.

Macroeconomic and Regional Demand Trends

Management reiterated that macroeconomic headwinds continue to depress demand for aesthetic procedures, with some patient spending likely deferred rather than lost entirely. Asia delivered mixed results, and the company’s long‑term strategy in China, including a repurposed Guangzhou entity and a spa‑focused approach, is still in early stages with timing and impact uncertain.

M&A Environment and Deal History

On the strategic front, Inmode described a challenging environment for mergers and acquisitions, citing elevated private‑company valuations that make deals less attractive. Executives also referenced past attempts at acquisitions and a failed sale effort in 2025 that contributed to a difficult year, reinforcing their cautious stance on pursuing transactions at unfavorable prices.

Guidance and Outlook

The company reiterated its 2026 outlook, projecting revenue between $365 million and $375 million, non‑GAAP gross margin of 74% to 76%, non‑GAAP operating income of $73 million to $78 million and non‑GAAP diluted EPS of $1.33 to $1.38. With Q1 delivering $82.0 million of revenue, a 75% non‑GAAP gross margin, 17% non‑GAAP operating margin and $0.25 in non‑GAAP EPS, Inmode is positioning guidance as achievable while acknowledging ongoing macro and margin challenges.

Inmode’s call suggests a company navigating a transition phase, balancing incremental growth and innovation against tighter margins and demand uncertainty. For investors, the story hinges on whether commercial restructuring, international expansion and new products can restore earnings momentum, with the robust balance sheet and active buybacks offering some downside support while management works through near‑term pressures.